Skip to main content
Top
Published in: European Child & Adolescent Psychiatry 6/2006

01-09-2006 | ORIGINAL CONTRIBUTION

Treatment of ADHD with French maritime pine bark extract, Pycnogenol®

Authors: Jana Trebatická, Soňa Kopasová, Zuzana Hradečná, Kamil Činovský, Igor Škodáček, Ján Šuba, Jana Muchová, Ingrid Žitňanová, Iweta Waczulíková, Peter Rohdewald, Zdeňka Ďuračková

Published in: European Child & Adolescent Psychiatry | Issue 6/2006

Login to get access

Abstract

Attention Deficit/Hyperactivity Disorder (ADHD) is the most common psychiatric disorder in children. Pycnogenol®, an extract from the bark of the French maritime pine, consisting of phenolic acids, catechin, taxifolin and procyanidins, has shown improvement of ADHD in case reports and in an open study. Aim of the present study was to evaluate the effect of Pycnogenol® on ADHD symptoms. Sixty-one children were supplemented with 1 mg/kg/day Pycnogenol® or placebo over a period of 4 weeks in a randomised, placebo-controlled, doubleblind study. Patients were examined at start of trial, 1 month after treatment and 1 month after end of treatment period by standard questionnaires: CAP (Child Attention Problems) teacher rating scale, Conner’s Teacher Rating Scale (CTRS), the Conner’s Parent Rating Scale (CPRS) and a modified Wechsler Intelligence Scale for children. Results show that 1-month Pycnogenol® administration caused a significant reduction of hyperactivity, improves attention and visual–motoric coordination and concentration of children with ADHD. In the placebo group no positive effects were found. One month after termination of Pycnogenol® administration a relapse of symptoms was noted. Our results point to an option to use Pycnogenol as a natural supplement to relieve ADHD symptoms of children.
Literature
1.
go back to reference Barkley RA (1990) Attention deficit hyperactivity disorder: a handbook for diagnosis and treatment. Guilford Press, New York Barkley RA (1990) Attention deficit hyperactivity disorder: a handbook for diagnosis and treatment. Guilford Press, New York
2.
go back to reference Biederman J (2005) Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 57:1215–1220PubMedCrossRef Biederman J (2005) Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 57:1215–1220PubMedCrossRef
3.
go back to reference Buitelaar JK, Danckaerts M, Gillberg C, Zuddas A, Becker K, Bouvard M, Fagan J, Gadoros J, Harpin V, Hazell P, Johnson M, Lerman-Sagie T, Soutullo CA, Wolanczyk T, Zeiner P, Fouche DS, Krikke-Workel J, Zhang S, Michelson D (2004) A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescent with ADHD. Eur Child Adolesc Psychiatry 13:249–257PubMed Buitelaar JK, Danckaerts M, Gillberg C, Zuddas A, Becker K, Bouvard M, Fagan J, Gadoros J, Harpin V, Hazell P, Johnson M, Lerman-Sagie T, Soutullo CA, Wolanczyk T, Zeiner P, Fouche DS, Krikke-Workel J, Zhang S, Michelson D (2004) A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescent with ADHD. Eur Child Adolesc Psychiatry 13:249–257PubMed
4.
go back to reference Conners CK, Sitarenios G, Oarker JDA, Epstein JN (1998) The revised Conners’ Parent Rating Scale (CPRS-R): factor structure, reliability, and Criterion Validity. J Abnorm Child Psychol 26:257–268PubMedCrossRef Conners CK, Sitarenios G, Oarker JDA, Epstein JN (1998) The revised Conners’ Parent Rating Scale (CPRS-R): factor structure, reliability, and Criterion Validity. J Abnorm Child Psychol 26:257–268PubMedCrossRef
5.
go back to reference Dulcan MK, Popper CW (1991) Concise guide to child and adolescent psychiatry. American Psychiatric Press, Washington Dulcan MK, Popper CW (1991) Concise guide to child and adolescent psychiatry. American Psychiatric Press, Washington
6.
go back to reference Ďuračková Z, Muchová J, Sivoňová M, Chovanová Z, Hauserová M, Blažíček P, Trebatická J, Rohdewal P (2004) Oxidative stress in pathophysiology of attention deficit hyperactivity disorder and its influence by a polyphenolic natural extracts, pycnogenol. In: Hoikkala A, Soidinsal O, Wähälä K (eds) XXII International Conference on Polyphenols “Polyphenols communications 2004” Helsinki, Finland, 25–28 August 2004. Jyväskyla, Gummerus Printing, pp 177–178, ISBN 952-10-1977-8 Ďuračková Z, Muchová J, Sivoňová M, Chovanová Z, Hauserová M, Blažíček P, Trebatická J, Rohdewal P (2004) Oxidative stress in pathophysiology of attention deficit hyperactivity disorder and its influence by a polyphenolic natural extracts, pycnogenol. In: Hoikkala A, Soidinsal O, Wähälä K (eds) XXII International Conference on Polyphenols “Polyphenols communications 2004” Helsinki, Finland, 25–28 August 2004. Jyväskyla, Gummerus Printing, pp 177–178, ISBN 952-10-1977-8
7.
go back to reference Fitzpatrick DF, Bin B, Rohdewald P (1998) Endothelium-dependent vascular effects of Pycnogenol. J Cardiovasc Pharmacol 32:509–515PubMedCrossRef Fitzpatrick DF, Bin B, Rohdewald P (1998) Endothelium-dependent vascular effects of Pycnogenol. J Cardiovasc Pharmacol 32:509–515PubMedCrossRef
8.
go back to reference Gillberg C, Gillberg IC, Rasmussen P, Kadesjo B, Soderstrom H, Rasatam M, Johnson M, Rothenberger A, Niklasson L (2004) Co-existing disorders in ADHD – implications for diagnosis and intervention. Eur Child Adolesc Psychiatry 13:180–192CrossRef Gillberg C, Gillberg IC, Rasmussen P, Kadesjo B, Soderstrom H, Rasatam M, Johnson M, Rothenberger A, Niklasson L (2004) Co-existing disorders in ADHD – implications for diagnosis and intervention. Eur Child Adolesc Psychiatry 13:180–192CrossRef
9.
go back to reference Grosse Düweler K, Rohdewald P (2000) Urinary metabolites of French maritime pine bark extract in humans. Pharmazie 55:364–368 Grosse Düweler K, Rohdewald P (2000) Urinary metabolites of French maritime pine bark extract in humans. Pharmazie 55:364–368
10.
go back to reference Hanley JL (1999) Attention deficit disorder. Impact Communications Inc, Green Bay Hanley JL (1999) Attention deficit disorder. Impact Communications Inc, Green Bay
11.
12.
go back to reference Ingram DK, Shimada A, Spangler EL, Ikari H, Hengemihle J, Kuo H, Greig N (1996) Cognitive enhancement. New strategies for stimulating cholinergic, glutamatergic, and nitric oxide systems. Ann NY Acad Sci 786:348–361PubMed Ingram DK, Shimada A, Spangler EL, Ikari H, Hengemihle J, Kuo H, Greig N (1996) Cognitive enhancement. New strategies for stimulating cholinergic, glutamatergic, and nitric oxide systems. Ann NY Acad Sci 786:348–361PubMed
13.
go back to reference Kaminester DD (1997) Attention Deficit Hyperactivity Disorder and methylphenidate: when society misunderstands medicine. McGill J Med 3:105–114 Kaminester DD (1997) Attention Deficit Hyperactivity Disorder and methylphenidate: when society misunderstands medicine. McGill J Med 3:105–114
14.
go back to reference Kubička L, Bursik R, Jirásek J (1973) PDW – Prague child Wechsler. Psychodiagnostic and didactic tests, Bratislava (in Slovak) Kubička L, Bursik R, Jirásek J (1973) PDW – Prague child Wechsler. Psychodiagnostic and didactic tests, Bratislava (in Slovak)
15.
go back to reference Liu F, Zhang Y, Lau BHS (1999) Pycnogenol® improves learning impairment and memory deficit in senescence-accelerated mice. J Anti Aging Med 2:349–355 Liu F, Zhang Y, Lau BHS (1999) Pycnogenol® improves learning impairment and memory deficit in senescence-accelerated mice. J Anti Aging Med 2:349–355
16.
go back to reference Malá E (2000) Hyperkinetické poruchy (F90) In: Hort V, Hrdlička M, Kocourková J, Malá E (eds) Dětská a adolescentní psychiatrie. Portál, Praha pp 307–314 Malá E (2000) Hyperkinetické poruchy (F90) In: Hort V, Hrdlička M, Kocourková J, Malá E (eds) Dětská a adolescentní psychiatrie. Portál, Praha pp 307–314
17.
go back to reference Masao H (2000) Pycnogenol®’s therapeutic effect in improving ADHD symptoms in children. Mainichi Shimbun, Oct. 21 Masao H (2000) Pycnogenol®’s therapeutic effect in improving ADHD symptoms in children. Mainichi Shimbun, Oct. 21
18.
go back to reference Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108:E83PubMedCrossRef Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108:E83PubMedCrossRef
19.
go back to reference Packer L, Rimbach G, Virgili F (1999) Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, Pycnogenol. Free Rad Biol Med 27:704–724PubMedCrossRef Packer L, Rimbach G, Virgili F (1999) Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, Pycnogenol. Free Rad Biol Med 27:704–724PubMedCrossRef
20.
go back to reference Paclt I, Florian J (1998) Dotazník pro rodiče (CPQ-Conners instrukce). In: Paclt I, Florian J Psychofarmakoterapie dětského a dorostového věku. Praha, Grada Publishing, pp 296–303 (in Slovak) Paclt I, Florian J (1998) Dotazník pro rodiče (CPQ-Conners instrukce). In: Paclt I, Florian J Psychofarmakoterapie dětského a dorostového věku. Praha, Grada Publishing, pp 296–303 (in Slovak)
21.
go back to reference Passwater RA (1998) All about Pycnogenol®. Avery Publishing Group, New York Passwater RA (1998) All about Pycnogenol®. Avery Publishing Group, New York
22.
go back to reference Pogun S, Kuhar MJ (1994) Regulation of neurotransmitter reuptake by nitric oxide. Ann NY Acad Sci 738:305–315PubMed Pogun S, Kuhar MJ (1994) Regulation of neurotransmitter reuptake by nitric oxide. Ann NY Acad Sci 738:305–315PubMed
23.
go back to reference Rohdewald PJ (2005) Pycnogenol®, French maritime pine bark extract In: Coates PM, Blackman MR, Cragg G, Levine M, Moss J, White J (eds) Encyclopedia of dietary supplements. Marcel Dekker, New York, pp 545–553, ISBN 0-8247-5504-9 Rohdewald PJ (2005) Pycnogenol®, French maritime pine bark extract In: Coates PM, Blackman MR, Cragg G, Levine M, Moss J, White J (eds) Encyclopedia of dietary supplements. Marcel Dekker, New York, pp 545–553, ISBN 0-8247-5504-9
25.
go back to reference Stanislavov R, Nikolova V (2005) Prelox® Plus testosterone for achieving fertilization in previously infertile men. Eur Bull Drug Res 13: 7–13 Stanislavov R, Nikolova V (2005) Prelox® Plus testosterone for achieving fertilization in previously infertile men. Eur Bull Drug Res 13: 7–13
26.
go back to reference Stough C, Ryan J, Croft K (2004) Anti-oxidants to ameliorate normal cognitive deterioration due to age. Presented at the International Conference On Healthy Ageing and Longevity. Sydney, Australia, March 5–7, 2004 Stough C, Ryan J, Croft K (2004) Anti-oxidants to ameliorate normal cognitive deterioration due to age. Presented at the International Conference On Healthy Ageing and Longevity. Sydney, Australia, March 5–7, 2004
27.
go back to reference Tenenbaum S, Paull JC, Sparrow EC, Dodd DK, Green L (2002) An experimental comparison of Pycnogenol® and methylphenidate in adults with Attention-Deficit/Hyperactivity Disorder (ADHD). J Atten Disord 6:49–60PubMed Tenenbaum S, Paull JC, Sparrow EC, Dodd DK, Green L (2002) An experimental comparison of Pycnogenol® and methylphenidate in adults with Attention-Deficit/Hyperactivity Disorder (ADHD). J Atten Disord 6:49–60PubMed
28.
go back to reference Trebatická J, Škodáček I, Šuba J, Kopasová S, Hradečná Z, Činovský K, Rohdewald P, Ďuračková Z (2004) Treatment success of ADHD by Pycnogenol®. In: Hoikkala A, Soidinsal O, Wähälä K (eds) XXII International Conference on Polyphenols “Polyphenols communications 2004” Helsinki, Finland, 25–28 August 2004. Jyväskyla, Gummerus Printing, pp 179–180, ISBN 952-10-1977-8 Trebatická J, Škodáček I, Šuba J, Kopasová S, Hradečná Z, Činovský K, Rohdewald P, Ďuračková Z (2004) Treatment success of ADHD by Pycnogenol®. In: Hoikkala A, Soidinsal O, Wähälä K (eds) XXII International Conference on Polyphenols “Polyphenols communications 2004” Helsinki, Finland, 25–28 August 2004. Jyväskyla, Gummerus Printing, pp 179–180, ISBN 952-10-1977-8
29.
go back to reference Yamada K, Noda Y, Nakayama S, Komori Y, Sugihara H, Hasegawa T, Nabeshima T (1995) Role of nitric oxide in learning and memory and in monoamine metabolism in the rat brain. Br J Pharmacol 115:852–858PubMed Yamada K, Noda Y, Nakayama S, Komori Y, Sugihara H, Hasegawa T, Nabeshima T (1995) Role of nitric oxide in learning and memory and in monoamine metabolism in the rat brain. Br J Pharmacol 115:852–858PubMed
Metadata
Title
Treatment of ADHD with French maritime pine bark extract, Pycnogenol®
Authors
Jana Trebatická
Soňa Kopasová
Zuzana Hradečná
Kamil Činovský
Igor Škodáček
Ján Šuba
Jana Muchová
Ingrid Žitňanová
Iweta Waczulíková
Peter Rohdewald
Zdeňka Ďuračková
Publication date
01-09-2006
Publisher
Steinkopff-Verlag
Published in
European Child & Adolescent Psychiatry / Issue 6/2006
Print ISSN: 1018-8827
Electronic ISSN: 1435-165X
DOI
https://doi.org/10.1007/s00787-006-0538-3

Other articles of this Issue 6/2006

European Child & Adolescent Psychiatry 6/2006 Go to the issue

ORIGINAL CONTRIBUTION

Autism and developmental delay